| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Departments of 1Clinical Genetics, 2Gynecology and Obstetrics, and 3Pathology, University Hospital of Aarhus, Aarhus, Denmark.
 |
ABSTRACT |
|---|
TOP
 ABSTRACT MATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
METHODS: A total of 270 consecutively collected, histologically confirmed hydatidiform moles were classified by ploidy using karyotyping and flow cytometry. The parental origin of the genome was determined by analysis of microsatellite polymorphisms. Data on clinical features and pathology reports were collected for each patient.
RESULTS: The observed frequency of persistent trophoblastic disease in patients with triploid moles was 0 of 105, (95% confidence interval 0–2.8%), whereas 28 of 162 patients with diploid molar pregnancies developed persistent trophoblastic disease (P < .001). Patients with a diploid mole and an initial hCG level lower than 49,000 units per liter did not develop persistent trophoblastic disease (P = .03).
CONCLUSION: The risk of persistent trophoblastic disease after a triploid mole is very low. By combining the present data with data from published studies with valid ploidy assessment, the frequency of persistent trophoblastic disease in patients with triploid moles is 0 of 196 (95% confidence interval 0–1.5%). We suggest that the surveillance program for patients with triploid molar pregnancies is shortened. Initial hCG less than 49,000 units per liter is a possible predictor of low risk of persistent trophoblastic disease in women with diploid molar pregnancies, but this observation needs confirmation in larger studies.
LEVEL OF EVIDENCE: II-2
Traditionally, a hydatidiform mole is classified as either a complete or a partial mole based on gross morphology and histopathology.3,4 Complete moles most frequently have a diploid karyotype as opposed to partial moles, which most often are triploid. Usually, diploid moles derive from fertilization of an "empty" egg with either a haploid sperm (homozygosity) or by dispermy (heterozygosity).5,6 A minority of diploid moles have biparental genomes. Triploid moles arise by dispermy and thus have 2 paternal sets and 1 maternal set of chromosomes to the genome.
Several attempts to describe risk factors for postmolar persistent trophoblastic disease have been made. Persistent trophoblastic disease is mainly associated with complete moles but has also been reported with partial moles.7,8 Some studies have shown that patients with high maternal age, excessive uterine size, markedly elevated initial hCG, positive history of hydatidiform mole, and marked trophoblastic proliferation have an increased risk of persistent trophoblastic disease after a complete mole. Other studies, however, could not confirm these findings.13,14
In this study we took the complementary view: Can we find predictive factors to identify molar patients without a risk of developing persistent trophoblastic disease? In an earlier study on 105 moles, we found that of 42 women with triploid moles, none developed persistent trophoblastic disease.15 This study extends our previous work.
|
MATERIALS AND METHODS |
|---|
|
TOP
ABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
We received and inspected 387 samples with the naked eye and under a dissection microscope (x25), finding 313 samples with vesicular villi (Ø > 1 mm) possibly representing hydatidiform mole. To diagnose molar pregnancy, 1 pathologist (E.S.H.) reviewed the original slides using the criteria of Szulman and Surti4 without knowledge of the ploidy or primary histopathologic diagnosis. After the review, 270 conceptuses were diagnosed as hydatidiform moles. Of the 43 excluded samples, 14 could not be revised due to lack of original histopathologic material.
We used karyotyping and flow cytometry to determine the ploidy of the molar tissue. Karyotyping was successful in 246 (91%) molar samples. Infection and formalin fixation were the main reasons for not obtaining metaphases. Eight moles were hypotriploid or hypertriploid, and 2 were hypodiploid or hyperdiploid and were classified as triploid or diploid, respectively. In 135 moles the DNA ploidy was determined by flow cytometry of unfixed interphase nuclei using the preparation techniques described by Vindelov16 with trout and chicken erythrocyte nuclei as controls. In 2 moles, the ploidy was determined by analysis of microsatellite polymorphisms.
The parental origin of the genome in the diploid moles was assessed by analysis of polymorphic DNA markers. Standard techniques were used to isolate DNA from molar tissue and parental blood samples. The analyses of DNA markers in the early part of the study have been described previously (Sunde L. Genetic analyses of hydatidiform mole with conceptual and practical implications. PhD thesis, University of Aarhus, Denmark 1990). In 109 diploid moles, DNA was amplified by polymerase chain reaction using 10 primer pairs (D13S634, D13S305, D13S258, D18S51, D18S391, D18S978, D21S11, D21S141, D21S1435, X22) flanking microsatellite loci with a heterozygosity frequency of 67–93%. The polymerase chain reaction products were resolved by capillary electrophoresis with an ABI prism 310 Genetic Analyzer (Applied Biosystems, Naerum, Denmark). The polymorphisms were analyzed using ABI prism GeneScan software (Applied Biosystems). A mole was classified as androgenetic when the mole and the patient had no identical alleles in at least 2 loci. Androgenetic moles were classified as homozygous (P1P1) if all, and at least 4, successfully analyzed loci showed homozygosity. Androgenetic moles were classified as heterozygous (P1P2) when having a XY karyotype or when the mole was heterozygous in at least 1 locus or both. In 3 cases, maternal DNA was lacking and the moles were classified as androgenetic and homozygous, because they were homozygous in all of 10 loci.
Data on clinical features and chemotherapy was collected from gynecologic and oncologic hospital records. All patients had at least 6 months of follow-up from evacuation date, and the median follow-up time was 10.4 years. We classified patients as having persistent trophoblastic disease if they were treated with chemotherapy. Methotrexate was the first choice of treatment to all patients. The Regional Committee on Biomedical Research Ethics of Aarhus County approved the project, and all patients gave informed consent. Logistic regression model, confidence intervals (assuming binomial distribution), and differences between groups (using the 
2 test or Fisher exact test where appropriate) were analyzed with Stata 8.2 statistical software (StataCorp LP, College Station, TX).
|
RESULTS |
|---|
|
TOP
ABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
Another 8 patients, 1 with a triploid and 7 with diploid moles, had delayed normalization of hCG levels but were cured without chemotherapy. Five of these achieved normal hCG values after a second evacuation. Three patients (with diploid moles) had persistently low hCG values (< 60 units per liter) for 4, 12, and 23 months, reaching undetectable values eventually. All of the 242 molar patients with spontaneous remission remained free of disease through the follow-up period (6 months to 17 years).
None of the patients with triploid or tetraploid molar pregnancies were treated with chemotherapy; 28 of 162 patients (17.3%) with a diploid mole developed persistent trophoblastic disease (P < .001) (Fig. 1). The observed frequency of persistent trophoblastic disease after a triploid mole was 0 of 105, (95% confidence interval [CI] 0–2.8%).
|
As noted above, 43 samples with vesicular villi were excluded by the histopathologic review. Among these, 26 gestations were triploid. None of the 26 additional patients with triploid gestations developed persistent trophoblastic disease, and thus, 0 of 131 (95% CI 0–2.3%) patients with triploid gestations originally suspected of hydatidiform mole developed persistent trophoblastic disease (data not shown).
Secondarily, we looked for factors that could point out patients with a low risk of persistent trophoblastic disease after a diploid mole. Table 2 gives the frequency of persistent trophoblastic disease after diploid moles stratified by the parental origin of the molar genome. Among the 162 diploid moles, 149 (92.0%) were androgenetic and 12 were biparental. Of the androgenetic moles, 18 (12.1%) were heterozygous. In 1 mole the parental origin could not be determined. Although not significant, the frequency of persistent trophoblastic disease was lower in patients with androgenetic, homozygous, or biparental moles (16.7% and 16.8%) than in patients with androgenetic, heterozygous moles (22.2%). In Table 3, maternal age less than 40 years, nonexcessive uterine size, initial hCG level less than 100,000 units per liter, and parental origin of the genome were evaluated as predictors of low risk of persistent trophoblastic disease among women with diploid moles. Using a multiple logistic regression model, none of the variables were predictors of spontaneous remission in diploid molar patients, although all parameters, though not significantly, reduced the risk of persistent trophoblastic disease. However, we did observe that none of 19 patients with an initial hCG level below 49,000 units per liter developed persistent trophoblastic disease (P = .03).
|
|
|
DISCUSSION |
|---|
|
TOP
ABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
One problem in identifying predictive factors for spontaneous remission is the identification of the group of patients with true gestational trophoblastic neoplasia. We defined patients with persistent trophoblastic disease as those who were given chemotherapy. Our data were consecutively collected in a well-organized public health care system with reliable registration and central treatment of gestational trophoblastic disease. Because the frequency of persistent trophoblastic disease was as low as 17.3% among the patients with diploid moles, because all but 2 patients needed at least 3 courses of methotrexate to obtain remission, and because all of the patients in the nonpersistent trophoblastic disease group remained free of disease in the follow-up period, we believe that by far most of our patients with persistent trophoblastic disease truly had gestational trophoblastic neoplasia and that we did not overlook any case of gestational trophoblastic neoplasia. To secure the validity of the ploidy, we avoided flow cytometry on formalin-fixed, paraffin-embedded tissue.
Our observation of no cases of persistent trophoblastic disease after triploid moles substantiates those of Lawler et al17 and Ohama et al.18 These 2 studies were also based on consecutively collected samples and determination of ploidy by reliable genetic techniques. Combining our results with theirs, the observed frequency of persistent trophoblastic disease in patients with triploid molar pregnancies adds to 0 of 196 (95% CI 0–1.5%).
Cases of triploid mole succeeded by choriocarcinoma have been reported.19,20 This is expectable because choriocarcinoma can succeed every type of pregnancy. Thus, the confidence intervals for the risk of persistent trophoblastic disease after a triploid mole and after a normal pregnancy probably overlap.
The risk of persistent trophoblastic disease after a triploid mole is very low and may even approach zero. We suggest that the surveillance program for patients with triploid molar pregnancies be shortened. An abbreviated follow-up period would imply less anxiety and shorter delay of child bearing for these women. To apply molar triploidy as a predictor of low risk of persistent trophoblastic disease, obtaining a valid ploidy is crucial. It is thus important to use reliable techniques like karyotyping or flow cytometry on fresh tissue with 2 external controls.14,21
We secondarily evaluated possible predictors of spontaneous remission in women with diploid molar pregnancies. The observed frequency of persistent trophoblastic disease after a diploid mole was 17.3% in this study as in other studies.13,22–24 Wake et al25 observed that patients with androgenetic, homozygous moles less frequently required chemotherapy treatment (0%) compared with patients with androgenetic, heterozygous moles (60%). Studies by Lawler et al17 and Fisher and Lawler26 could not confirm that patients with androgenetic, heterozygous moles had a higher frequency of persistent trophoblastic disease. Likewise, we found no significant differences in the frequency of persistent trophoblastic disease in moles stratified by parental origin. Maternal age younger than 40 years, nonexcessive uterine size, and an initial hCG less than 100,000 units per liter reduced, however not significantly, the risk of persistent trophoblastic disease. With an initial hCG lower than 49,000 units per liter, though, we observed a significantly reduced frequency of persistent trophoblastic disease (P = .03). Two studies report that women reaching a serum hCG value less than 50 units per liter or a urinary hCG less than 40 units per liter within 4 to 8 weeks after the first evacuation have a low risk of persistent trophoblastic disease.27,28 A prompt predictor of low risk of persistent trophoblastic disease would be of greater benefit to the patients. Low initial hCG is a potential predictor of spontaneous remission in women with diploid moles, but the best estimate of a cutoff level and its clinical applicability need to be studied in larger studies.
Triploid hydatidiform moles carry a very low risk of persistent trophoblastic disease. Further studies of low risk factors, such as low initial se-hCG, for diploid molar pregnancies are important. Our observations furthermore imply that diploid and triploid moles possibly represent 2 different biologic entities with different clinical properties.
|
Footnotes |
|---|
Corresponding author: Isa Niemann, MD, Department of Clinical Genetics, Bartholin Bygningen, Aarhus Sygehus, 8000, Aarhus C, Denmark; e-mail: isani{at}as.aaa.dk.
doi:10.1097/01.AOG.0000210635.24543.3b
|
REFERENCES |
|---|
|
TOP
ABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
2. Franke HR, Risse EKJ, Kenemans P, Vooijs GP, Stolk JG. Epidemiologic features of hydatidiform mole in the Netherlands. Obstet Gynecol 1983;62:613–6.
3. Szulman AE, Surti U. The syndromes of hydatidiform mole: I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978;131:665–71.[Medline]
4. Szulman AE, Surti U. The syndromes of hydatidiform mole: II. Morphologic evolution of the complete and partial mole. Am J Obstet Gynecol 1978;132:20–7.[Medline]
5. Kajii T, Ohama K. Androgenetic origin of hydatidiform mole. Nature 1977;268:633–4.[Medline]
6. Ohama K, Kajii T, Okamoto E, Fukuda Y, Imaizumi K, Tsukahara M, et al. Dispermic origin of XY hydatidiform moles. Nature 1981;29:551–2.
7. Cheung AN, Khoo US, Lai CY, Chan KY, Xue WC, Cheng DK, et al. Metastatic trophoblastic disease after initial diagnosis of partial hydatidiform mole: genotyping and chromosome in situ hybridization analysis. Cancer 2004;100:1411–7.[Medline]
8. Goto S, Yamada A, Ishizuka T, Tomoda Y. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol 1993;48:165–70.[Medline]
9. Ayhan A, Tuncer ZS, Halilzade H, Kucukali T. Predictors of persistent disease in women with complete hydatidiform mole. J Reprod Med 1996;41:591–4.[Medline]
10. Bandy LC, Clarke-Pearson DL, Hammond CB. Malignant potential of gestational trophoblastic disease at the extreme ages of reproductive life. Obstet Gynecol 1984;64:395–9.
11. Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med 1996;335:1740–8.
12. Felemban AA, Bakri YN, Alkharif HA, Altuwaijri SM, Shalhoub J, Berkowitz RS. Complete molar pregnancy—clinical trends at King Fahad Hospital, Riyadh, Kingdom of Saudi Arabia. J Reprod Med 1998;43:11–3.[Medline]
13. Mungan T, Kuscu E, Dabakoglu T, Senoz S, Ugur M, Cobanoglu O. Hydatidiform mole: clinical analysis of 310 patients. Int J Gynecol Obstet 1996;52:233–6.[Medline]
14. Lage JM, Mark SD, Roberts DJ, Goldstein DP, Bernstein MR, Berkowitz RS. A flow cytometric study of 137 fresh hydropic placentas: correlation between types of hydatidiform moles and nuclear DNA ploidy. Obstet Gynecol 1992;79:403–10.[Medline]
15. Sunde L, Mogensen B, Olsen S, Nielsen V, Christensen IJ, Bolund L. Flow cytometric DNA analyses of 105 fresh hydatidiform moles with correlations to prognosis. Analytical Cell Pathol 1996;12:99–114.
16. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323–7.[Medline]
17. Lawler SD, Fisher RA, Dent J. A prospective genetic study of complete and partial hydatidiform moles. Am J Obstet Gynecol 1991;164:1270–7.[Medline]
18. Ohama K, Ueda K, Okamoto E, Takenaka M, Fujiwara A. Cytogenetic and clinicopathologic studies of partial moles. Obstet Gynecol 1986;62:259–62.
19. Bagshawe KD, Lawler SD, Paradinas FJ, Dent J, Brown P, Boxer GM. Gestational trophoblastic tumours following initial diagnosis of hydatidiform mole. Lancet 1990;335:1074–6.[Medline]
20. Seckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, et al. Choriocarcinoma and partial hydatidiform moles. Lancet 2000;356:36–9.[Medline]
21. Frierson HF. Flow Cytometric analysis of ploidy in solid neoplasms: comparison of fresh tissues with formalin-fixed paraffin-embedded specimens. Hum Pathol 1988;19:290–4.[Medline]
22. Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients. Obstet Gynecol 1975;45:1–8.
23. Lawler SD, Fisher RA. Genetic studies in hydatidiform mole with clinical correlations. Placenta 1987;8:77–88.[Medline]
24. Hancock BW, Tidy JA. Current management of molar pregnancy. J Reprod Med 2002;47:347–54.[Medline]
25. Wake N, Seki T, Fujita H, Okubo H, Sakai K, Okuyama K, et al. Malignant potential of homozygous and heterozygous complete moles. Cancer Res 1984;44:1226–30.
26. Fisher RA, Lawler SD. Heterozygous complete hydatidiform moles: do they have a worse prognosis than homozygous complete moles? Lancet 1984:51.
27. Wolfberg AJ, Berkowitz R, Goldstein DP, Feltmate C, Lieberman E. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol 2005;106:548–52.
28. Pisal N, Tidy J, Hancock B. Gestational trophoblastic disease: is intensive follow-up essential in all women? BJOG 2004;111:1449–51[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
